Skip to content

Eli Lilly LLY Price / book

Price / book at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
7.3×+2.1×
Pfizer logo
PfizerPFE
1.8×+0.2×
Amgen logo
AmgenAMGN
20.6×-6.3×
Biogen logo
BiogenBIIB
1.4×+0.3×
ResMed logo
ResMedRMD
-0.9×
Cencora logo
CencoraCOR
18×-35.2×

Other financials

Income statement

See full
Revenue$19.8B+55.5%
Gross profit$16.2B+54.4%
Net income$7.4B+168%
EPS (diluted)$8.26+170%

Balance sheet

See full
Cash & equivalents$5.3B+70.8%
Total debt$43.4B+12.6%
Total equity$31.2B+97.9%
Total assets$116.58B+30.4%

Cash flow

See full
Operating cash flow$5.3B+220%
CapEx$2.3B+54.0%
Free cash flow$3.0B+1,828%

Valuation

See full
Market cap$991.62B+10.8%
Enterprise value$1.03T+10.6%
P/E39.2×-41.4×
P/S13.7×-4.5×

Profitability

See full
Gross margin82.8%+1.1pp
Net margin35%+12.3pp

Returns & leverage

See full
Return on equity107.6%+29.9pp
Debt / equity1.4×-1.1×
Current ratio1.5×+0.1×

Where this comes from

Calculated from Eli Lilly’s reported figures.

Based on the most recent quarter.

The official record: Eli Lilly’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Eli Lilly's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Eli Lilly's price / book?
Eli Lilly (LLY) reported price / book of 26.3× in Q1 2026.
How has Eli Lilly's price / book changed year-over-year?
Eli Lilly's price / book decreased by 44.0% year-over-year, from 47× to 26.3×.
What is the long-term trend for Eli Lilly's price / book?
Over 4 years (2021 to 2025), Eli Lilly's price / book has grown at a 6.3% compound annual growth rate (CAGR), from 117.9× to 150.3×.
What does price / book mean?
How the market price compares to the company's accounting net worth.
How do you interpret price / book?
Below 1.0 can flag a market discount to book value (common for distressed or asset-heavy firms); high values reflect intangible value the balance sheet doesn't capture. Most informative for financials and asset-heavy businesses.
How does price / book compare across companies?
A core valuation gauge for banks and insurers; weak for asset-light firms where book value understates economic value.